Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 6770-6778

  Assikis, Vasily J ^a   Do, Kim Anh ^a   Wen, Sijin ^a   Wang, Xuemei ^a   Cho Vega, Jeong Hee ^a   Brisbay, Shawn ^a   Lopez, Remigio ^a   Logothetis, Christopher J ^a   Troncoso, Patricia ^a   Papandreou, Christos N ^a   McDonnell, Timothy J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CASPASE; CHROMOGRANIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; SEROTONIN; STAT3 PROTEIN; UVOMORULIN;

ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CORRELATION ANALYSIS; EVALUATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; METASTASIS POTENTIAL; METHODOLOGY; NEUROENDOCRINE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; STATISTICAL ANALYSIS; TUMOR LOCALIZATION;

AGED; ANDROGENS; CELL PROLIFERATION; COHORT STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 6044267986     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0275     Document Type: Article

References (48)

1. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila) 1993;72:3888-95.
2. Kirk D. MRC study: when to commence treatment in advanced prostate cancer. Prostate Cancer Prostatic Dis 1997;1:11-5.
3. Scher HI. Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer (Phila) 2003;97:758-71.
4. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012-9.
5. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336-41.
6. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer (Phila) 2003;97:772-8.
7. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
8. David AK, Khwaja R, Hudes GR. Treatments for improving survival of patients with prostate cancer. Drugs Aging 2003;20:683-99.
9. De S, Chen J, Narizhneva NV, et al. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003;278:39044-50.
10. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
11. Kuniyasu H, Ukai R, Johnston D, et al. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 2003;9;2185-94.
12. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-48.
13. Ahlgren G, Pedersen K, Lundberg S, et al. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000;42:274-9.
14. Hansson J, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Scand J Urol Nephrol Suppl 2003;212:28-36.
15. Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol 2001;159:837-43.
16. Coombes KR, Highsmith WE, Krogmann TA, et al. Identifying and quantifying sources of variation in microarray data using high-density cDNA membrane arrays. J Comput Biol 2002;9:655-69.
17. Jonasch E, Do KA, Logothetis C, McDonnell TJ. Applications and issues for tissue arrays in target and drug discovery. New York: John Wiley & Sons; 2004. p. 73-90.
18. Cox DR, Oakes, D. Analysis of survival data. New York: Chapman & Hall, 1984.
19. Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000;31:406-14.
20. Zhang XQ, Kondrikov D, Yuan TC, et al. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 2003;22 6704-16.
21. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998;4:50-7.
22. McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997;157:569-74.
23. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
24. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-21.
25. Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer (Phila) 1998;82:168-75.
26. Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001;28:20-4.
27. Matsushima H, Goto T, Hosaka Y, Kitamura T, Kawabe K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer (Phila) 1999;85:1822-27.
28. Baisch H. Elevated Ki-67 expression is correlated with TNFalpha-and IFNgamma-induced apoptosis in tumour cells. Cell Prolif 2002;35:333-42.
29. Lein M, Jung K, Ortel B, et al. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002;21:2089-96.
30. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science (Wash DC) 1991;251:1451-5.
31. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999;53:707-13.
32. Yoshiura K, Kanai Y, Ochiai A, et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995;92:7416-9.
33. Kallakury BV, Sheehan CE, Winn-Deen E, et al. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer (Phila) 2001;92:2786-95.
34. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001;105:391-402.
35. Eklof Spink K, Fridman SG, Weis WI. Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. EMBO J 2001;20:6203-12.
36. Bryden AA, Hoyland JA, Freemont AJ, et al. E-cadherin and beta-catenin are down-regulated in prostatic bone metastases. BJU Int 2002;89:400-3.
37. Dahiya R, Lee C, Haughney PC, et al. Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines. Urology 1996;48:963-70.
38. Jones HE, Eaton CL, Barrow D, et al. Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 1997;30:219-31.
39. Toning N, Dagnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 2003;56:142-9.
40. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-5.
41. Malik SN, Brattain M, Ghosh PM, et al. I. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-71.
42. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66.
43. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer (Phila) 1994;74:416-23.
44. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20:707-18.
45. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer (Phila) 1996;77:1254-62.
46. Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer, how aggressive should we be? Arch Surg 2000;135:530-4; discussion 534-5.
47. Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197:233-41; discussion 241-2.
48. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery (St Louis) 2002;132:620-6; discussion 626-7.